- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2024-06-21
2024-12-31
2025-06-30
36
NCT04640480
SN BioScience
SN BioScience
INTERVENTIONAL
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in participants with advanced solid tumors. Dose escalation will occur using a modified accelerated titration design (ATD). All participants will receive SNB 101 in different cohorts. SNB 101 will be administered intravenously to participants on day 1 and day 15 of each 28 day treatment cycle until progressive disease, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. A Safety Review Committee will determine dose escalation, de-escalation, and modification and the MTD/RP2D based on DLTs and other safety information.
Each participant will undergo a screening period, a treatment period, and a follow-up period. Participants will be followed until death, withdrawal of consent, or end of study, whichever occurs first. During the treatment period, participants will receive SNB-101 (dose range: 5 mg/m2 to 50 mg/m2) intravenously on day 1 and day 15 of each 28 day cycle. Dose reductions are permitted after the DLT observation period, which occurs during the first 28 days of treatment (cycle 1). Participants may permanently or temporarily (at the investigator's discretion) discontinue SNB-101. If a participant experiences a DLT or unacceptable toxicity, SNB-101 treatment should be interrupted until the observed toxicity returns to baseline or ≤ grade 1 toxicity. The start of the next cycle can be delayed up to 2 weeks at the investigator's discretion.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2020-10-22 | N/A | 2023-11-22 |
2020-11-16 | N/A | 2023-11-27 |
2020-11-23 | N/A | 2023-11 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
Treatment
Allocation:
Non Randomized
Interventional Model:
Sequential
Masking:
None
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| EXPERIMENTAL: Cohort 1 SNB-101 5/8mg/m2 Q2W IV | DRUG: SNB-101
|
| EXPERIMENTAL: Cohort 2 SNB-101 10/16mg/m2 Q2W IV | DRUG: SNB-101
|
| EXPERIMENTAL: Cohort 3 SNB-101 20/32mg/m2 Q2W IV | DRUG: SNB-101
|
| EXPERIMENTAL: Cohort 4 SNB-101 30/48mg/m2 Q2W IV | DRUG: SNB-101
|
| EXPERIMENTAL: Cohort 5 SNB-101 40/64mg/m2 Q2W IV | DRUG: SNB-101
|
| EXPERIMENTAL: Cohort 6 SNB-101 45/72mg/m2 Q2W IV | DRUG: SNB-101
|
| EXPERIMENTAL: Cohort 7 SNB-101 50/80mg/m2 Q2W IV | DRUG: SNB-101
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Dose-limiting toxicity(DLT) | * All participants who take at least 1 dose of SNB-101 will be assessed. * DLTs will be presented by dose group and the MTD determined. *DLTs : 1) Hematological toxicity * Grade 4 thrombocytopenia * Grade 3 thrombocytopenia with clinically significant bleeding * Grade 4 neutropenia lasting > 7 days * ≥ grade 3 febrile neutropenia 2) Nonhematological toxicity * Any ≥ grade 3 nonhematological toxicity 3) Liver function abnormalities * Patients who have bone or liver metastasis with the following increases will be considered a DLT: 1. Baseline AST or ALT = 2.5 to 5× ULN, then AST or ALT that increases to >8× ULN 2. Baseline ALP = 2.5 to 5×ULN, then ALP increases to >8×ULN 4) Any toxicity related to SNB-101 that results in a treatment delay of more than 2 weeks. | up to 18 months(depending on safety variable) |
| Permanent discontinuation of SNB-101 and dose reduction due to adverse events(AEs) | Definition of permanent discontinuation of SNB-101: 1. Experiencing a DLT or intolerable toxicity during the DLT observation period. 2. Experiencing life-threatening Grade 4 adverse events (AE). 3. Experiencing Grade 2 interstitial lung disease or Grade 4 infusion related reaction/ hypersensitivity. * Descriptive statistics for continuous variables, frequency and percentage for categorical variables | up to 18 months(depending on safety variable) |
| Number of participants with clinically meaningful changes in Laboratory test results from baseline | * Hematology: RBC count, WBC count, hemoglobin, hematocrit, platelets, mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration, WBC differential count, ANC. * Serum biochemistry: BUN, creatinine, glucose (random), aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, total protein, albumin, Ca, P, K, Na, Cl, CO2, GGT, and LDH. * Coagulation: prothrombin time and international normalized ratio. * Viral serology: viral serology test for HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus antibody. The test can be waived for participants who have results within 28 days prior to screening. * Urinalysis: specific gravity, protein, pH, blood, and ketones. * Descriptive statistics for continuous variables, frequency and percentage for categorical variables | up to 18 months(depending on safety variable) |
| Number of participants with clinically meaningful changes in Vital signs from baseline | * Vital signs include blood pressure(sitSBP/sitDBP), heart rate, respiratory rate, and body temperature. Change from baseline or previous visit will be described. * After each infusion of SNB-101, vital signs will be monitored every 30 minutes for 3 hours on an outpatient basis. * Descriptive statistics for continuous variables, frequency and percentage for categorical variables | up to 18 months(depending on safety variable) |
| Electrocardiogram(ECG) results | * ECG data will be collected at screening, C1D1, C3D1 and EOT. * ECG measurement at C1D1 and C3D1 will be performed after PK sampling at the end of the infusion (90 min.), 2.5 hours and 24 hours after drug administration. * ECG QT interval will be assessed for the safety endpoint(e.g. QTc prolongation) * Descriptive statistics for continuous variables, frequency and percentage for categorical variables | up to 18 months(depending on safety variable) |
| Number of clinically significant Chest radiograph findings(chest x-ray, CXR) | * Number of clinically significant chest radiograph findings from chest x-ray. * Descriptive statistics for continuous variables, frequency and percentage for categorical variables | up to 18 months(depending on safety variable) |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Area under the plasma concentration-time curve(AUC) | - The PK parameter will be calculated for SN-38 based on plasma concentrations measured from the PK blood samples. | 4 months |
| Maximum plasma concentration(Cmax) | - The PK parameter will be calculated for SN-38 based on plasma concentrations measured from the PK blood samples. | 4 months |
| Time to Cmax(Tmax) | The PK parameter will be calculated for SN-38 based on plasma concentrations measured from the PK blood samples. | 4 months |
| Clearance(CL) | The PK parameter will be calculated for SN-38 based on plasma concentrations measured from the PK blood samples. | 4 months |
| Volume of distribution(Vd) | The PK parameter will be calculated for SN-38 based on plasma concentrations measured from the PK blood samples. | 4 months |
| Terminal half-life(t1/2) | The PK parameter will be calculated for SN-38 based on plasma concentrations measured from the PK blood samples. | 4 months |
| Elimination rate constant | The PK parameter will be calculated for SN-38 based on plasma concentrations measured from the PK blood samples. | 4 months |
| The objective response rate(ORR) | * Determination of the antitumor efficacy of SNB-101 * All participants who take at least 1 dose of SNB-101 and have at least 1 post dose efficacy assessment will be assessed. * Computed tomography scans (abdomen/pelvic, chest) will be performed at screening and every 8 weeks (± 7 days) for tumor assessment. * ORR is defined as the percentage of participants who have achieved either complete response or partial response to the therapeutic intervention. Response is measured per RECIST version 1.1 as assessed by the investigator at the local site. * ORR will be presented as frequencies and percentages. | up to 18 months(depending on subject cycles) |
| Disease control rate(DCR) | * Determination of the antitumor efficacy of SNB-101 * All participants who take at least 1 dose of SNB-101 and have at least 1 post dose efficacy assessment will be assessed. * Computed tomography scans (abdomen/pelvic, chest) will be performed at screening and every 8 weeks (± 7 days) for tumor assessment. * DCR is defined as the percentage of participants who have achieved either complete response, partial response, or stable disease to the therapeutic intervention. Response is measured per RECIST version 1.1 as assessed by the investigator at the local site. * DCR will be presented as frequencies and percentages. | up to 18 months(depending on subject cycles) |
| Overall survival(OS) | * Determination of the antitumor efficacy of SNB-101 * All participants who take at least 1 dose of SNB-101 and have at least 1 post dose efficacy assessment will be assessed. * Computed tomography scans (abdomen/pelvic, chest) will be performed at screening and every 8 weeks (± 7 days) for tumor assessment. * OS is defined as the time from the first dose of SNB-101 to death from any cause. * OS median survival times will be calculated using the Kaplan Meier method. | up to 18 months(depending on subject cycles) |
| Progression-free survival(PFS) | * Determination of the antitumor efficacy of SNB-101 * All participants who take at least 1 dose of SNB-101 and have at least 1 post dose efficacy assessment will be assessed. * Computed tomography scans (abdomen/pelvic, chest) will be performed at screening and every 8 weeks (± 7 days) for tumor assessment. * PFS is defined as the time from the first dose of SNB-101 to documented disease progression or death due to any cause, whichever occurs earlier. * PFS median survival times will be calculated using the Kaplan Meier method. | up to 18 months(depending on subject cycles) |
| Time to progression(TTP) | * Determination of the antitumor efficacy of SNB-101 * All participants who take at least 1 dose of SNB-101 and have at least 1 post dose efficacy assessment will be assessed. * Computed tomography scans (abdomen/pelvic, chest) will be performed at screening and every 8 weeks (± 7 days) for tumor assessment. * TTP is defined as the time from the first dose of SNB-101 to objective tumor progression. * TTP will be calculated using the Kaplan Meier method. | up to 18 months(depending on subject cycles) |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: Jaehong Kim Phone Number: +82-31-757-3849 Email: jhkim@snbioscience.com |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
19 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
